One Lot of Xanax XR Pulled Over Dissolution Failure — Here’s What to Check
A specific batch of alprazolam extended-release tablets may not release the drug at the intended rate, according to the U.S. Food and Drug Administration.
Representative Image. Photo Source:PxHere | Health Safety
A voluntary recall has been issued for a single lot of Xanax XR (alprazolam) 3 mg extended-release tablets in the United States, after quality testing showed the tablets did not meet dissolution specifications. The affected bottles — manufactured in Ireland and distributed between August 2024 and May 2025 — were sent to wholesalers and retail pharmacies nationwide. Distributor Viatris Specialty LLC of Morgantown, West Virginia initiated the recall on March 17, and the U.S. Food and Drug Administration subsequently classified it as a Class II recall.
The recall is narrow in scope: one lot, one strength, one product. The vast majority of patients on alprazolam are prescribed generic versions, which are entirely unaffected. This piece breaks down exactly what the recall means — and what, if anything, you need to do.
Check Your Medication
Is Your Bottle Affected?
The recall targets one specific lot only. Check your bottle label against these details.
Lot Number
8177156
Expiry Date
Feb 28, 2027
Strength
3 mg XR
NDC Number
58151-506-91
Count
60 tablets
Distributed
Aug 27, 2024 – May 29, 2025
Manufactured In
Ireland
U.S. Bottles Distributed
51
🔍 Type Your Lot Number
The recall was initiated by Viatris Specialty LLC, the Morgantown, West Virginia-based distributor, after the specific lot — manufactured at a Viatris facility in Ireland — produced “out-of-specification dissolution results” during quality testing. The issue does not affect any other lot, strength, or product. As the distributor confirmed, the recall operates at the retailer level — meaning pharmacies are responsible for pulling and returning the stock, not patients at home.
The California State Board of Pharmacy issued an urgent directive asking all licensed pharmacies to immediately review their quality assurance and recall procedures. No adverse events or patient reactions linked to Lot 8177156 have been reported as of mid-April 2026.
What “Failed Dissolution” Actually Means
Xanax XR is an extended-release formulation designed to deliver alprazolam slowly into the bloodstream over several hours. When a tablet “fails dissolution,” that controlled release is compromised. The tabs below show three possible outcomes. Learn more about alprazolam from NIH MedlinePlus.
Drug release over 24 hours — Ideal profile
The extended-release matrix releases alprazolam at a controlled rate, maintaining stable plasma concentrations. This is the intended behaviour and what dissolution testing is designed to confirm.
Drug release — Potential dose dumping scenario
If the XR matrix breaks down prematurely, the full 3 mg dose may potentially release faster than intended — similar to an immediate-release tablet. This could potentially cause excessive sedation early on, followed by a period without therapeutic coverage. This scenario is known in pharmaceutical terms as “dose dumping.” The FDA has not confirmed this occurred in the recalled lot; it is a risk associated with dissolution failure in extended-release formulations.
Drug release — Subtherapeutic scenario
If the tablet dissolves too slowly or incompletely, insufficient alprazolam may reach the bloodstream. For a patient relying on the medication to manage panic disorder, this could mean the medication is less effective than expected or delivers an inconsistent dose. In some cases, this type of inconsistency may also contribute to breakthrough anxiety symptoms. The recall notice did not report any specific patient outcomes from this lot.
Understanding Class II: The FDA’s Recall Ladder
The FDA assigns a class to every recall based on assessed health risk. Click each class to learn more.
Class II recall: The FDA defines this as a situation in which use of or exposure to a product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. For the Xanax XR recall, the recall classification was assigned after the FDA evaluated the submitted dissolution data — it is not a finding that patients were actually harmed.
Brand vs. Generic: Who Is Actually Affected
A key reassurance point in this recall is the distinction between brand-name and generic alprazolam.
recalled
A Viatris spokesperson confirmed: “The vast majority of patients in the U.S. are dispensed generic alprazolam, which this recall does not affect. Further, the voluntary recall is at the retailer level, as agreed with the FDA, meaning that patients do not need to take any action. Wholesalers and Retailers (pharmacies) have been provided with instruction on how to return the product in question.”
Timeline of the Recall
Manufacturing defects in extended-release tablets are typically linked to issues during production — coating inconsistencies that affect the dissolution matrix, variability in tablet compression, or deviations in raw material quality. These problems are often identified during routine in-process quality control or post-market stability testing, and are not always visible to consumers. The FDA’s enforcement reporting system tracks and publishes all such actions.
Xanax XR was developed specifically to address the limitations of immediate-release alprazolam — the XR version uses a specialised polymer matrix to maintain stable blood concentrations over a full day, reducing the anxiety “spikes and dips” that can occur with shorter-acting formulations. This delivery mechanism is also why a dissolution failure in this specific product is a more meaningful quality concern than it might be in a standard tablet. For more background on how FDA recalls are classified and actioned, see KarmActive’s earlier coverage of the SinuCleanse recall.
What Officials Have Said
Viatris Specialty LLC — Official Company Statement
“Patient safety and the quality of our medicines are of the utmost importance to Viatris. The voluntary recall of Xanax XR in the U.S. is specific to one lot of one strength (3mg) of the brand product only, and no other batches of the Xanax XR brand product, or its generics, are impacted. The vast majority of patients in the U.S. are dispensed generic alprazolam, which this recall does not affect. Further, the voluntary recall is at the retailer level, as agreed with the FDA, meaning that patients do not need to take any action. Wholesalers and Retailers (pharmacies) have been provided with instruction on how to return the product in question.”
California State Board of Pharmacy — Official Recall Alert
“The risk to the patient associated with this event is considered to be negligible. To date, no reports of adverse reactions associated with this lot have been received.”
California State Board of Pharmacy — Directive to Pharmacies
“Immediately review their quality assurance and recall policies and procedures.”
If You Think Your Bottle Is Affected
Tick each step as you go — or read through at your own pace.
- Check the label first. Look for Lot 8177156 on the side or bottom of the bottle. If you moved pills to a weekly organiser, contact your pharmacy to confirm your most recent refill lot number — pharmacies can trace this through their dispensing records using NDC 58151-506-91.
- Do not stop the medication without speaking to a doctor. Stopping any benzodiazepine suddenly can cause serious withdrawal effects, including seizures. This is particularly important with alprazolam. Contact your prescribing physician before making any change to your regimen.
- Speak to your pharmacist. Pharmacies have been instructed by Viatris on how to handle returns. If your bottle is part of the recall, they can process the return and replace it with a bottle from a compliant lot at no extra cost to you.
- Monitor how your medication feels. If you’ve been experiencing breakthrough anxiety or unusual drowsiness shortly after taking the tablet over recent months, note the timing and tell your doctor. This can help assess whether the dissolution issue may have been a factor.
- Report adverse effects to the FDA. If you believe you experienced a side effect related to this lot, you can report it through the FDA MedWatch portal. Reports from patients help the agency track post-market safety in real time.
ℹ️ This checklist is for informational purposes only. It does not replace medical advice. All medication changes should be discussed with a licensed healthcare provider.
Summary
The nationwide recall involved one lot of Xanax XR 3 mg extended-release tablets — Lot 8177156, expiry February 2027 — distributed in the United States between August 2024 and May 2025 by Viatris Specialty LLC. The recall was initiated in March 2026 and was classified by the U.S. Food and Drug Administration as a Class II action, following dissolution testing that produced out-of-specification results. Official statements from both Viatris and the California State Board of Pharmacy noted that no adverse patient events have been reported, the risk is considered negligible, and the action applies at the retailer level. Generic alprazolam products, which account for the majority of U.S. alprazolam prescriptions, were confirmed to be outside the scope of this recall. For related coverage on FDA product recalls and health safety, see KarmActive’s reporting on the Herbalife Class II alert and the Systane eye drops recall.
